Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

Alan F. List, Gordon W. Dewald, John M. Bennett et al. · New England Journal of Medicine · 2006 · 1.3K citations

Medicine, Hematology, Pharmacology +17

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Luca Malcovati, Eva Hellström‐Lindberg, David Bowen et al. · Blood · 2013 · 667 citations · Full text

Medicine, Hematology, Oncology +13

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Luca Malcovati, Elli Papaemmanuil, David Bowen et al. · Blood · 2011 · 494 citations · Full text

Medicine, Genetics, Molecular Genetics +17

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag et al. · Blood · 2011 · 480 citations · Full text

Medicine, Hematology, Pharmacology +14

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil et al. · Blood · 2015 · 428 citations

Life Sciences, Genetics, Molecular Genetics +11